Filed: 5/13/2024ACC: 0000950123-24-004535
📋 What this filing means
MAYO CLINIC filed this quarterly 13F‑HR report disclosing 5 equity positions with a total reported market value of $6.15M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
5
Positions
$6.15M
Total AUM (reported)
1.23M
Total Shares
Allocation by class
COMMON$6.15M100.0%
Portfolio Concentration
Top 3$5.72M93.1%
4–10$421.6K6.9%
Top 3 weight
93.1%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 1.23M
Sole
Full voting authority
1.23M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole5
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings5
Rows:
Zentalis Pharmaceuticals Inc.
SOLEShares187.14K
TypeSH
Market value$2.95M
48.00%
Sole
187.14K
Shared
0.00
None
0.00
MSCI ACWI ETF
SOLEShares17.36K
TypeSH
Market value$1.91M
31.11%
Sole
17.36K
Shared
0.00
None
0.00
Perspective Therapeutics Inc.
SOLEShares724.64K
TypeSH
Market value$862.3K
14.03%
Sole
724.64K
Shared
0.00
None
0.00
Neuroone Medical Technologies
SOLEShares181.75K
TypeSH
Market value$218.1K
3.55%
Sole
181.75K
Shared
0.00
None
0.00
UNITY BIOTECHNOLOGY INC
SOLEShares124.08K
TypeSH
Market value$203.5K
3.31%
Sole
124.08K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals Inc.SOLE | Common | 187.14K | SH | $2.95M 48.00% | 187.14K | 0.00 | 0.00 |
MSCI ACWI ETFSOLE | Common | 17.36K | SH | $1.91M 31.11% | 17.36K | 0.00 | 0.00 |
Perspective Therapeutics Inc.SOLE | Common | 724.64K | SH | $862.3K 14.03% | 724.64K | 0.00 | 0.00 |
Neuroone Medical TechnologiesSOLE | Common | 181.75K | SH | $218.1K 3.55% | 181.75K | 0.00 | 0.00 |
UNITY BIOTECHNOLOGY INCSOLE | Common | 124.08K | SH | $203.5K 3.31% | 124.08K | 0.00 | 0.00 |